Amgen Inc

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value

$465.45−0.56 (-0.12%)

Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%

Amgen EVENITY (romosozumab-aqqg by Quarter

Name: Amgen EVENITY (romosozumab-aqqg by Quarter (AMGN)
Creator: Amgen

EVENITY (romosozumab-aqqg — Postmenopausal Osteoporosis) — Rest of World (ROW) product sales ($M) ($M)

Quarterly Annual

Amgen EVENITY (romosozumab-aqqg: $164M in Q2 2026, up 33.3% from a year earlier. That is the highest of the 29 quarters on record here.

Latest, Q2 2026

164

Period ended Jun 30, 2026

Change on a year earlier

+33.3%

123 in Q2 2025

History

29 quarters

Since Q2 2019

Sources

Documents cited below

Where the Q2 2026 figure comes from

Source: Form 10-Q (filed 2026-08-05) ↗

Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

Period	Ended	EVENITY (romosozumab-aqqg — Postmenopausal Osteoporosis) — Rest of World (ROW) product sales ($M) ($M)	Year on year	Source
Q2 2026	Jun 30, 2026	164	+33.3%	Form 10-Q (filed 2026-08-05) ↗
Q1 2026	Mar 31, 2026	131	+7.4%	Form 10-Q (filed 2026-05-01) ↗
Q4 2025	Dec 31, 2025	131	+23.6%	Form 10-K (filed 2026-02-13) ↗
Q3 2025	Sep 30, 2025	124	+12.7%	Form 10-Q (filed 2025-11-05) ↗
Q2 2025	Jun 30, 2025	123	+11.8%	Form 10-Q (filed 2026-08-05) ↗
Q1 2025	Mar 31, 2025	122	+15.1%	Form 10-Q (filed 2026-05-01) ↗
Q4 2024	Dec 31, 2024	106	+34.2%	Form 10-K (filed 2026-02-13) ↗
Q3 2024	Sep 30, 2024	110	+18.3%	Form 10-Q (filed 2025-11-05) ↗
Q2 2024	Jun 30, 2024	110	+23.6%	Form 10-Q (filed 2025-08-06) ↗
Q1 2024	Mar 31, 2024	106	+17.8%	Form 10-Q (filed 2025-05-02) ↗
Q4 2023	Dec 31, 2023	79	+16.2%	Form 10-K (filed 2026-02-13) ↗
Q3 2023	Sep 30, 2023	93	+43.1%	Form 10-Q (filed 2024-10-31) ↗
Q2 2023	Jun 30, 2023	89	+45.9%	Form 10-Q (filed 2024-08-07) ↗
Q1 2023	Mar 31, 2023	90	+50.0%	Form 10-Q (filed 2024-05-03) ↗
Q4 2022	Dec 31, 2022	68	+61.9%	Form 10-K (filed 2025-02-14) ↗
Q3 2022	Sep 30, 2022	65	+18.2%	Form 10-Q (filed 2023-10-31) ↗
Q2 2022	Jun 30, 2022	61	+17.3%	Form 10-Q (filed 2023-08-04) ↗
Q1 2022	Mar 31, 2022	60	+20.0%	Form 10-Q (filed 2023-04-28) ↗
Q4 2021	Dec 31, 2021	42	+40.0%	Form 8-K (amgenq42021earningsrelease.htm, filed 2022-02-07) ↗
Q3 2021	Sep 30, 2021	55	+1,000.0%	Form 8-K (amgn-2021930xq3ex991.htm, filed 2021-11-02) ↗
Q2 2021	Jun 30, 2021	52	-14.8%	Form 8-K (amgn-2021630xq2ex991.htm, filed 2021-08-03) ↗
Q1 2021	Mar 31, 2021	50	-20.6%	Form 8-K (amgn-2021331xq1ex991.htm, filed 2021-04-27) ↗
Q4 2020	Dec 31, 2020	30	-48.3%	Form 8-K (amgn-20201231xq4ex991.htm, filed 2021-02-02) ↗
Q3 2020	Sep 30, 2020	5	-89.4%	Form 8-K (amgn-2020930xq3ex991.htm, filed 2020-10-28) ↗
Q2 2020	Jun 30, 2020	61	+144.0%	Form 8-K (amgn-2020630xq1ex991.htm, filed 2020-07-28) ↗
Q1 2020	Mar 31, 2020	63	–	Form 8-K (amgn-2020331xq1ex991.htm, filed 2020-04-30) ↗
Q4 2019	Dec 31, 2019	58	–	Form 8-K (amgn-20191231xq4ex991.htm, filed 2020-01-30) ↗
Q3 2019	Sep 30, 2019	47	–	Form 8-K (amgn-2019930xq3exhibit.htm, filed 2019-10-29) ↗
Q2 2019	Jun 30, 2019	25	–	Form 8-K (amgn-2019630xq2exhibit991f.htm, filed 2019-07-30) ↗

Cite this data

StockData. (2026). Amgen EVENITY (romosozumab-aqqg ($M), quarterly Q2 2019–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-evenity-row

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.